Therapeutic targeting of PD-1/PD-L1 blockade by novel small-molecule inhibitors recruits cytotoxic T cells into solid tumor microenvironment

BACKGROUND: Inhibiting programmed cell death protein 1 (PD-1) or PD-ligand 1 (PD-L1) has shown exciting clinical outcomes in diverse human cancers. So far, only monoclonal antibodies are approved as PD-1/PD-L1 inhibitors. While significant clinical outcomes are observed on patients who respond to th...

Descripción completa

Detalles Bibliográficos
Autores principales: Acúrcio, Rita C., Pozzi, Sabina, Carreira, Barbara, Pojo, Marta, Gómez-Cebrián, Nuria, Casimiro, Sandra, Fernandes, Adelaide, Barateiro, Andreia, Farricha, Vitor, Brito, Joaquim, Leandro, Ana Paula, Salvador, Jorge A R, Graça, Luís, Puchades-Carrasco, Leonor, Costa, Luís, Satchi-Fainaro, Ronit, Guedes, Rita C., Florindo, Helena F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9310269/
https://www.ncbi.nlm.nih.gov/pubmed/35863821
http://dx.doi.org/10.1136/jitc-2022-004695

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9310269/
https://www.ncbi.nlm.nih.gov/pubmed/35863821
http://dx.doi.org/10.1136/jitc-2022-004695

Ejemplares similares